Personalis logo

PersonalisNASDAQ: PSNL

Profile

Sector:

Healthcare

Country:

United States

IPO:

20 June 2019

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$246.56 M
-63%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
48%vs. sector
-64%vs. 3y high
47%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:43:51 GMT
$3.49-$0.20(-5.42%)

Dividend

No data over the past 3 years
$25.71 M$15.53 M
$25.71 M-$39.09 M

Analysts recommendations

Institutional Ownership

PSNL Latest News

Personalis: Resetting My Strategy Following The Q2 Beat
seekingalpha.com18 August 2024 Sentiment: POSITIVE

PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
globenewswire.com11 July 2024 Sentiment: POSITIVE

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
businesswire.com31 May 2024 Sentiment: POSITIVE

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis' ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus' commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung can.

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
businesswire.com22 May 2024 Sentiment: POSITIVE

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois. “As the body of studies continue.

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
Seeking Alpha28 February 2024 Sentiment: POSITIVE

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript
Seeking Alpha07 November 2023 Sentiment: POSITIVE

Personalis, Inc. (NASDAQ:PSNL ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Research and Development Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Mark Massaro - VTIG Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call.

Personalis to Announce First Quarter 2023 Financial Results
Business Wire19 April 2023 Sentiment: POSITIVE

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Personalis: Revisiting The Investment Thesis
Seeking Alpha17 April 2023 Sentiment: POSITIVE

Today, we put diagnostic firm Personalis, Inc. back in the spotlight as the shares go for less than the company's net cash on the balance sheet. The company has brought in a new CEO and announced significant cost saving measures.

What type of business is Personalis?

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

What sector is Personalis in?

Personalis is in the Healthcare sector

What industry is Personalis in?

Personalis is in the Diagnostics & Research industry

What country is Personalis from?

Personalis is headquartered in United States

When did Personalis go public?

Personalis initial public offering (IPO) was on 20 June 2019

What is Personalis website?

https://www.personalis.com

Is Personalis in the S&P 500?

No, Personalis is not included in the S&P 500 index

Is Personalis in the NASDAQ 100?

No, Personalis is not included in the NASDAQ 100 index

Is Personalis in the Dow Jones?

No, Personalis is not included in the Dow Jones index

When was Personalis the previous earnings report?

No data

When does Personalis earnings report?

The next expected earnings date for Personalis is 28 February 2025